Related Experiment Videos

Lomefloxacin is an effective treatment of experimental bacterial keratitis

R P Kowalski1, E G Romanowski, K A Yates

  • 1Department of Ophthalmology, University of Pittsburgh and Medical Center, Pennsylvania 15213, USA. Kowalskirp@msx.upmc.edu

Cornea
|April 27, 2001
PubMed
Abstract

Insights

Lomefloxacin shows promise as a topical treatment for bacterial keratitis, effectively reducing bacterial counts in rabbit models. While equally effective against gram-positive bacteria, it was less potent than ciprofloxacin against gram-negative strains.

Area of Science:

  • Ophthalmology
  • Microbiology
  • Pharmacology

Background:

  • Bacterial keratitis is a serious eye infection requiring effective antimicrobial therapy.
  • Topical fluoroquinolones are commonly used, but resistance is a growing concern.

Purpose of the Study:

  • To evaluate lomefloxacin as a potential topical treatment for bacterial keratitis.
  • To compare the efficacy of lomefloxacin with ciprofloxacin in experimental keratitis models.

Main Methods:

  • Rabbit keratitis models were established using various bacterial pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens.
  • Corneas were treated with topical lomefloxacin (0.3%), ciprofloxacin (0.3%), or phosphate-buffered saline (PBS).
  • Bacterial viability was assessed by colony counts, and data were statistically analyzed.

Main Results:

  • Both lomefloxacin and ciprofloxacin significantly reduced bacterial colony counts compared to PBS controls (p < 0.05).
  • Lomefloxacin demonstrated equal efficacy to ciprofloxacin against gram-positive bacterial isolates.
  • Lomefloxacin was effective but less potent than ciprofloxacin against gram-negative bacterial isolates (p < 0.05).

Conclusions:

  • Lomefloxacin exhibits promising therapeutic potential for bacterial keratitis based on these experimental findings.
  • Further clinical investigations are warranted to establish the role of lomefloxacin in treating human bacterial keratitis.

Related Concept Videos